

Special Issue

Molecular Biology of Colorectal Cancers

Message from the Guest Editors

As known, CRC was one of the first tumors in which molecular mechanisms were investigated and confirmed. We now accept that tumors that look identical on microscopic grounds are different at the molecular level, and this explains the varying patient outcomes that we usually face in clinical practice. Tumors look alike but are not the same!

However, even in the era of molecular medicine and targeted therapies, most of the patients that develop metastatic CRC eventually die of disease with a poor quality of life and significant years of potential life lost, specially when ever younger people are getting affected by this disease. Much remains to be known about the mechanisms that contribute to the aggressive behaviour of CRC and factors predicting therapy response.

This special issue is devoted to recent research involving molecular mechanisms underlying colorectal carcinoma, including epigenetic changes, interaction with the environment, and analysis by omics technologies. A fascinating world is open to research, and we would like to invite you to join us in this issue in which we hope to shed some more light into the biology of this common and still lethal tumor.

Guest Editors

Dr. María Jesús Fernández Aceñero

Dr. Rodrigo Barderas Manchado

Dr. Javier Martínez Useros

Dr. Cristina Díaz del Arco

Deadline for manuscript submissions

closed (30 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/123045

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)